{"id":"NCT00801398","sponsor":"Endo Pharmaceuticals","briefTitle":"Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.","officialTitle":"An Open-Label, Ascending, Two-Part, Single- and Multiple-Dose Evaluation of the Safety, Pharmacokinetics, and Effectiveness of Oxymorphone for Acute Postoperatiave Pain in Pediatric Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02-17","primaryCompletion":"2011-04-18","completion":"2011-04-18","firstPosted":"2008-12-03","resultsPosted":"2019-02-27","lastUpdate":"2019-02-27"},"enrollment":58,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Postoperative Pain"],"interventions":[{"type":"DRUG","name":"Oxymorphone IR","otherNames":["Opana IR"]}],"arms":[{"label":"Oxymorphone IR","type":"EXPERIMENTAL"}],"summary":"When post-operative parenteral analgesia is discontinued, oral dosing with study medication may begin once the subject has developed a moderate level of pain as defined by a 100 mm VAS (pain intensity score greater than or equal to 40).\n\nThis post marketing study was required by the FDA. Endo Pharmaceuticals Inc. no longer promotes opioids and no longer markets OpanaÂ® ER.","primaryOutcome":{"measure":"Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of Oxymorphone IR Tablet","timeFrame":"Single Dose Timeframe: 15min, 30min, 1h, 2h, 3h, 4h, 6h or Rescue; Multiple Dose Timeframe: 15min, 30min, 1h, 2h, 3h, 4h, 6h, subsequent doses every 4-6 hours (Multiple Dose #1-11), and Early Termination","effectByArm":[{"arm":"Change From Baseline Single Dose of Oxymorphone IR: 5mg Tablet","deltaMin":-13.4,"sd":22.86},{"arm":"Change From Baseline Single Dose Oxymorphone IR: 10mg Tablet","deltaMin":-22.2,"sd":17.79},{"arm":"Change From Baseline Single Dose Oxymorphone IR: 15mg Tablet","deltaMin":-21.6,"sd":13.59},{"arm":"Change From Baseline Multiple Dose Oxymorphone IR: 5mg Tablet","deltaMin":-16.7,"sd":23.31},{"arm":"Change From Baseline Multiple Dose Oxymorphone IR: 10mg Tablet","deltaMin":0.5,"sd":9.56},{"arm":"Change From Baseline Multiple Dose Oxymorphone IR: 15mg Tablet","deltaMin":-17.4,"sd":13.46}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Nausea","Constipation","Pyrexia","Vomiting","Oxygen saturation decreased"]}}